Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Yasuhiro Horii"'
Autor:
Akira Mima, Yasuhiro Horii
Publikováno v:
Endocrinology, Diabetes & Metabolism, Vol 7, Iss 3, Pp n/a-n/a (2024)
ABSTRACT Objective Tirzepatide is an injectable peptide approved by the US Food and Drug Administration for the treatment of Type 2 diabetes (T2DM). Its weight‐loss effect primarily targets fat reduction; however, such effect on patients with chron
Externí odkaz:
https://doaj.org/article/670fbb084af44f7abaaf7adddf359374
Autor:
AKIRA MIMA, YASUHIRO HORII
Publikováno v:
In Vivo
Background/Aim: Renal anemia is a major complication in patients with chronic kidney disease (CKD) and hemodialysis, increasing morbidity and mortality. Roxadustat is a novel oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (PHI), whi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3635be177f1f8543561e0e0aba9bec9
https://europepmc.org/articles/PMC9301421/
https://europepmc.org/articles/PMC9301421/
Publikováno v:
Nihon Toseki Igakkai Zasshi. 28:1179-1184
CAPD (continuous ambulatory peritoneal dialysis) 排液の白濁は, 腹膜炎の重要な兆候であるが, 乳糜の混入による白濁排液と鑑別を要する場合が少なくない. 今回著者らは, 排液の白濁が脂肪成分の分
Autor:
Yasunori Watanabe, Katsuo Fuse, Tosiya Kobayashi, Yasuhiro Horii, Shin Yamamoto, Hiroaki Konishi, Yosihiro Naruse
Publikováno v:
Japanese Journal of Cardiovascular Surgery. 22:472-475
1982年より1991年までの間に当科で行った冠動脈再建術961例のうち, 周術期に脳梗塞を発症した12例を対象に周術期の脳梗塞について検討した. 症例の平均年齢は65±4歳, 術前の冠動脈危険因
Autor:
Tosiya Kobayasi, Yosihiro Naruse, Shin Yamamoto, Yasuhiro Horii, Katsuo Fuse, Yasunori Watanabe, Hiroaki Konishi
Publikováno v:
Japanese Journal of Cardiovascular Surgery. 21:566-569
72歳男性. 特発性間質性肺炎 (IIP) を伴う不安定狭心症の診断のもと冠動脈造影 (CAG) を施行し, LMTに90%の狭窄病変を認め, PTCAを施行したが約2か月後再び不安定狭心症となり, CAGでLMT 90%の再
Autor:
Haruhiro Toko, Tadashi Isomura, Hiroaki Shimomura, Yasushi Kitaura, Makoto Okabe, Shigekazu Fujioka, Hisayoshi Suma, Keishiro Kawamura, Yasuhiro Horii, Fumio Terasaki, Yumiko Kanzaki, Tetsuya Hayashi
Publikováno v:
Japanese circulation journal. 65(9)
Partial left ventriculectomy (PLV) can be used to treat refractory congestive heart failure caused by dilated cardiomyopathy (DCM). In order to understand the relationship between the underlying myocardial injury and early clinical outcomes after PLV
Autor:
Hideo Shiiki, Hiroshi Yamamoto, Yasuhiro Horii, Richard Bucala, Toshihiko Nishino, Kazuhiro Dohi, Zenji Makita
Publikováno v:
Human pathology. 26(3)
Numerous studies over the years have implicated advanced glycosylation end products (AGEs) in the pathogenesis of many of the complications of diabetes and normal aging. The recent development of specific antibodies against AGE-modified proteins has
Publikováno v:
Nephron. 62(1)
Interleukin 6 (IL-6) is an autocrine growth factor of cultured mesangial cells (MC) and intraglomerular IL-6 production is suggested to be closely associated with the pathogenesis of human mesangial proliferative glomerulonephritis (mesPGN). In this
Autor:
Helen Vlassara, Yasuhiro Horii, Manikkam Suthanthiran, Anthony Cerami, Sharon Brunelle, Zenji Makita, Prabodh K. Sehajpal, Zhi Yang
Publikováno v:
The Journal of Experimental Medicine
Advanced glycosylation endproducts (AGEs), the glucose-derived adducts that form nonenzymatically and accumulate on tissue proteins, are implicated in many chronic complications associated with diabetes and aging. We have previously described a monoc
Autor:
Toshio Hirano, Tetsuya Taga, Katsuhiko Yamasaki, Tadashi Matsuda, Bo Tang, Atsushi Muraguchi, Yasuhiro Horii, Sachiko Suematsu, Yuuichi Hirata, Hideo Yawata, Masatoshi Shimizu, Michiaki Kawano, Tadamitsu Kishimoto
Publikováno v:
International Archives of Allergy and Immunology. 88:29-33
Interleukin 6 (IL-6)/B cell stimulatory factor 2 is a multifunctional cytokine produced by both lymphoid and nonlymphoid cells. IL-6 regulates immune response, acute phase reaction, and hematopoiesis. It was found that IL-6 production by T cells is d